# MiniMed

> MiniMed develops insulin pumps, continuous glucose monitors, smart insulin pens and connected software for people with diabetes. Its SmartGuard algorithm links glucose sensing to automated insulin delivery, while MiniMed Go supports people who use injections. Founded as a business in 1983 by Alfred E. Mann, MiniMed became a Nasdaq-listed company in March 2026 and completed its separation from Medtronic in October 2026.

- **Founded:** 1983
- **Headquarters:** Los Angeles, United States
- **Founders:** Alfred E. Mann (Founder of the original MiniMed business)
- **Products:** MiniMed 780G system, MiniMed Flex system, Instinct sensor, made by Abbott, Simplera Sync sensor, MiniMed Go system / InPen
- **Notable:** MiniMed 670G received FDA approval on September 28, 2016, as the first hybrid closed-loop system., FDA approval of MiniMed 780G in the United States in April 2023., Resolved the December 2021 Northridge FDA warning letter in April 2023.

## Products & services

- **MiniMed 780G system** — Insulin pump system with SmartGuard automated background dosing and automatic correction doses up to every five minutes; U.S. approval in 2023. Current U.S. labeling includes type 1 diabetes ages 7+ and insulin-requiring type 2 diabetes ages 18+.
- **MiniMed Flex system** — Smartphone-controlled, screenless insulin pump cleared by the FDA in March 2026; approximately half the size of the 780G by the company’s stated comparison. U.S. launch with Simplera followed by Instinct integration.
- **Instinct sensor, made by Abbott** — All-in-one CGM for compatible MiniMed systems, with up to 15 days of wear. Compatibility depends on device, software and market.
- **Simplera Sync sensor** — Disposable all-in-one CGM for compatible MiniMed pump systems; current U.S. comparison lists six days of wear plus a 24-hour grace period.
- **MiniMed Go system / InPen** — Connects a reusable Bluetooth insulin pen, compatible CGM and app for dose tracking, dose calculations and missed-dose alerts; the user administers injections.
- **Extended infusion set** — Insulin infusion set designed for up to seven days of wear, used with compatible pump equipment.
- **CareLink** — Diabetes data software for reviewing and sharing glucose and insulin information with care teams and, through compatible tools, care partners.

## Achievements

- MiniMed 670G received FDA approval on September 28, 2016, as the first hybrid closed-loop system.
- FDA approval of MiniMed 780G in the United States in April 2023.
- Resolved the December 2021 Northridge FDA warning letter in April 2023.
- Began Nasdaq trading as MMED on March 6, 2026.
- MiniMed Flex FDA clearance announced March 18, 2026.
- Completed separation from Medtronic on October 15, 2026.

## Latest updates

- **2026-10** — Completed separation from Medtronic on October 15; Medtronic no longer held an equity stake. A new board composition was announced in October.
- **2026-10** — Reported an analysis linking greater response to Smart MDI alerts with better glucose outcomes; response-group comparisons establish association, not randomized proof of the effect of responding.
- **2026-09** — Reported first-quarter fiscal 2027 net sales of $843 million, up 16.6% as reported; the quarter benefited from an extra week. MiniMed Fit had been submitted to the FDA, and Flex had received CE Mark; projected launch dates remained forward-looking.
- **2026-08** — U.S. launch of MiniMed Flex with Instinct began August 17, according to the September earnings release.
- **2026-03** — IPO and Nasdaq trading followed by FDA clearance of MiniMed Flex.

## Links

- Website: https://www.minimed.com/
- LinkedIn: https://www.linkedin.com/company/minimed-diabetes
- Twitter/X: https://x.com/minimed
- YouTube: https://www.youtube.com/@minimed_US
- Instagram: https://www.instagram.com/minimed/
- Facebook: https://www.facebook.com/minimed
- TikTok: https://www.tiktok.com/@minimed

---

Profile page: https://yespress.io/minimed
Published by YesPress — https://yespress.io
Last updated: 2026-10-22